TWi Pharmaceuticals announces the first shipment of its generic product in the U.S. market.

2015.03.17  Taipei, Taiwan; Irvine, CA –TWi Pharmaceuticals, Inc. (“TWi”, 4180.TW) announced today that its wholly-owned subsidiary, TWi Pharmaceuticals USA, shipped the first generic product in its own label on March 16, 2015.  This makes TWi the first Taiwanese pharmaceutical company to directly sell generic pharmaceutical products under its own label in the U.S. market.

“Since forming TWi Pharmaceuticals USA in January 2014, we have focused our efforts on this launch in order to establish our presence in the U.S. market.  While this is an important milestone, it is only the first of many more to come,” said Tina Guilder, President of TWi Pharmaceuticals USA.  “I'm proud that our team has the distinct honor of being the first Taiwanese company to bring high-quality generic products to our customers and patients in the U.S.”

“We are extremely pleased that we have formally launched one of TWi's products under our own label in the U.S. market,” said Dr. Chih-Ming Chen, Chairman of TWi Pharmaceuticals, Inc.  “I would also like to take this opportunity to thank all of our employees for their valuable contribution in bringing this endeavor to fruition.  It's TWi's ongoing mission to provide the highest quality and yet affordable generic and new pharmaceutical products for patients globally.  We will continue to strive towards achieving that goal.”


About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Contact :
Eric Lin
Tel: +886-2-2657-3350 #407
Email: eric.lin@twipharma.com